vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and TMC the metals Co Inc. (TMC). Click either name above to swap in a different company.

FATE THERAPEUTICS INC is the larger business by last-quarter revenue ($1.4M vs $1.3M, roughly 1.1× TMC the metals Co Inc.). On growth, TMC the metals Co Inc. posted the faster year-over-year revenue change (2425.5% vs -26.4%). TMC the metals Co Inc. produced more free cash flow last quarter ($-11.5M vs $-112.0M). Over the past eight quarters, TMC the metals Co Inc.'s revenue compounded faster (159.0% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

The Metals Company, formerly DeepGreen Metals, is a Canadian deep sea mining exploration company. The company focuses on the mining of polymetallic nodules in the Clarion Clipperton Zone of the Pacific.

FATE vs TMC — Head-to-Head

Bigger by revenue
FATE
FATE
1.1× larger
FATE
$1.4M
$1.3M
TMC
Growing faster (revenue YoY)
TMC
TMC
+2451.9% gap
TMC
2425.5%
-26.4%
FATE
More free cash flow
TMC
TMC
$100.6M more FCF
TMC
$-11.5M
$-112.0M
FATE
Faster 2-yr revenue CAGR
TMC
TMC
Annualised
TMC
159.0%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FATE
FATE
TMC
TMC
Revenue
$1.4M
$1.3M
Net Profit
$-40.4M
Gross Margin
Operating Margin
-3470.9%
Net Margin
-3136.5%
Revenue YoY
-26.4%
2425.5%
Net Profit YoY
37.9%
-151.5%
EPS (diluted)
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
TMC
TMC
Q4 25
$1.4M
$1.3M
Q3 25
$1.7M
$1.3M
Q2 25
$1.9M
Q1 25
$1.6M
Q4 24
$1.9M
Q3 24
$3.1M
Q2 24
$6.8M
Q1 24
$1.9M
Net Profit
FATE
FATE
TMC
TMC
Q4 25
$-40.4M
Q3 25
$-32.3M
$-184.5M
Q2 25
$-34.1M
Q1 25
$-37.6M
Q4 24
Q3 24
$-47.7M
Q2 24
$-38.4M
Q1 24
$-48.0M
Operating Margin
FATE
FATE
TMC
TMC
Q4 25
-3470.9%
Q3 25
-1995.1%
-4134.4%
Q2 25
-1938.5%
Q1 25
-2534.1%
Q4 24
Q3 24
-1703.9%
Q2 24
-665.7%
Q1 24
-2652.9%
Net Margin
FATE
FATE
TMC
TMC
Q4 25
-3136.5%
Q3 25
-1852.4%
-13780.2%
Q2 25
-1786.6%
Q1 25
-2309.5%
Q4 24
Q3 24
-1551.0%
Q2 24
-567.4%
Q1 24
-2493.7%
EPS (diluted)
FATE
FATE
TMC
TMC
Q4 25
$0.11
Q3 25
$-0.27
$0.46
Q2 25
$-0.29
Q1 25
$-0.32
Q4 24
Q3 24
$-0.40
Q2 24
$-0.33
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
TMC
TMC
Cash + ST InvestmentsLiquidity on hand
$203.7M
$117.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$-33.4M
Total Assets
$318.9M
$181.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
TMC
TMC
Q4 25
$203.7M
$117.6M
Q3 25
$215.4M
$115.6M
Q2 25
$222.8M
Q1 25
$240.4M
Q4 24
$279.1M
Q3 24
$296.9M
Q2 24
$304.9M
Q1 24
$121.3M
Stockholders' Equity
FATE
FATE
TMC
TMC
Q4 25
$207.2M
$-33.4M
Q3 25
$234.1M
$-40.6M
Q2 25
$261.4M
Q1 25
$288.4M
Q4 24
$318.7M
Q3 24
$362.3M
Q2 24
$397.0M
Q1 24
$426.1M
Total Assets
FATE
FATE
TMC
TMC
Q4 25
$318.9M
$181.6M
Q3 25
$343.7M
$175.6M
Q2 25
$371.6M
Q1 25
$398.7M
Q4 24
$440.7M
Q3 24
$495.0M
Q2 24
$528.8M
Q1 24
$569.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
TMC
TMC
Operating Cash FlowLast quarter
$-106.1M
$-11.4M
Free Cash FlowOCF − Capex
$-112.0M
$-11.5M
FCF MarginFCF / Revenue
-8183.9%
-889.8%
Capex IntensityCapex / Revenue
434.8%
8.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
TMC
TMC
Q4 25
$-106.1M
$-11.4M
Q3 25
$-24.4M
$-11.5M
Q2 25
$-24.6M
Q1 25
$-33.8M
Q4 24
$-122.9M
Q3 24
$-29.4M
Q2 24
$-32.3M
Q1 24
$-33.4M
Free Cash Flow
FATE
FATE
TMC
TMC
Q4 25
$-112.0M
$-11.5M
Q3 25
$-26.6M
$-11.5M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
TMC
TMC
Q4 25
-8183.9%
-889.8%
Q3 25
-1526.5%
-859.4%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
TMC
TMC
Q4 25
434.8%
8.2%
Q3 25
126.5%
1.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
Q2 24
0.8%
Q1 24
4.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons